Everest Medicines Announces China NMPA’s Approval of Nefecon® for the Treatment of Primary IgA Nephropathy in Adult Patients USA – English 
Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today that China’s National Medical Products Administration (NMPA) has approved Nefecon® for the treatment of primary immunoglobulin A nephropathy (IgAN)…
AstraZeneca in collaboration with Indian Society of Nephrology (ISN) launches CKD Academy; top nephrologists to mentor medical professionals.
AstraZeneca India, a leading science-led biopharmaceutical company, announced the launch of their Chronic Kidney Disease Academy, in collaboration with the largest professional organization of nephrologists in India– Indian Society of Nephrology (ISN). This academy will offer module-based learning for clinicians…
